{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:52:32Z","timestamp":1794552752203,"version":"4.9.1"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06710-6","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:54:13Z","timestamp":1762502053000},"page":"5573-5591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phytochemicals in overcoming venetoclax resistance in acute myeloid leukemia: mechanistic insights and therapeutic potential"],"prefix":"10.1007","volume":"104","author":[{"given":"Suresh","family":"Prajapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmi","family":"Jyotishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-4388","authenticated-orcid":false,"given":"Reeshu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"3","key":"6710_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K (2019) Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol 20(3):175\u2013193","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"6710_CR2","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood.2022016090","volume":"141","author":"DM Moujalled","year":"2023","unstructured":"Moujalled DM et al (2023) Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia. Blood 141(6):634\u2013644","journal-title":"Blood"},{"issue":"1","key":"6710_CR3","doi-asserted-by":"publisher","first-page":"26418","DOI":"10.1038\/s41598-024-78221-9","volume":"14","author":"R Kawakatsu","year":"2024","unstructured":"Kawakatsu R et al (2024) The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia. Sci Rep 14(1):26418","journal-title":"Sci Rep"},{"issue":"6","key":"6710_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","volume":"15","author":"GO Nwosu","year":"2024","unstructured":"Nwosu GO et al (2024) Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis 15(6):413","journal-title":"Cell Death Dis"},{"key":"6710_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.semcancer.2020.06.014","volume":"80","author":"E Khatoon","year":"2022","unstructured":"Khatoon E et al (2022) Phytochemicals in cancer cell chemosensitization: current knowledge and future perspectives. Semin Cancer Biol 80:306\u2013339","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"6710_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/1947601911417177","volume":"2","author":"R Elkholi","year":"2011","unstructured":"Elkholi R, Floros KV, Chipuk JE (2011) The role of BH3-only proteins in tumor cell development, signaling, and treatment. Genes Cancer 2(5):523\u2013537","journal-title":"Genes Cancer"},{"issue":"3","key":"6710_CR7","doi-asserted-by":"publisher","first-page":"108240","DOI":"10.1016\/j.jbc.2025.108240","volume":"301","author":"S Raghuwanshi","year":"2025","unstructured":"Raghuwanshi S et al (2025) A novel FOXM1-BCL2A1 axis determines unfavorable response to venetoclax in AML. J Biol Chem 301(3):108240","journal-title":"J Biol Chem"},{"key":"6710_CR8","doi-asserted-by":"publisher","unstructured":"Garciaz S et al (2024) Venetoclax resistance in acute myeloid leukemia. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16061091","DOI":"10.3390\/cancers16061091"},{"key":"6710_CR9","doi-asserted-by":"publisher","first-page":"101036","DOI":"10.1016\/j.blre.2022.101036","volume":"59","author":"P Dhakal","year":"2023","unstructured":"Dhakal P et al (2023) Acute myeloid leukemia resistant to venetoclax-based therapy: what does the future hold? Blood Rev 59:101036","journal-title":"Blood Rev"},{"issue":"2","key":"6710_CR10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","volume":"5","author":"F Ong","year":"2022","unstructured":"Ong F, Kim K, Konopleva MY (2022) Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist 5(2):380\u2013400","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"6710_CR11","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjh.19314","volume":"204","author":"B Nachmias","year":"2024","unstructured":"Nachmias B et al (2024) Venetoclax resistance in acute myeloid leukaemia-clinical and biological insights. Br J Haematol 204(4):1146\u20131158","journal-title":"Br J Haematol"},{"key":"6710_CR12","doi-asserted-by":"publisher","unstructured":"Garciaz S et al (2021) Venetoclax in acute myeloid leukemia: molecular basis, evidences for preclinical and clinical efficacy and strategies to target resistance. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13225608","DOI":"10.3390\/cancers13225608"},{"issue":"7","key":"6710_CR13","doi-asserted-by":"publisher","first-page":"e0307662","DOI":"10.1371\/journal.pone.0307662","volume":"19","author":"T Tauchi","year":"2024","unstructured":"Tauchi T et al (2024) Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway. PLoS One 19(7):e0307662","journal-title":"PLoS One"},{"key":"6710_CR14","doi-asserted-by":"publisher","unstructured":"Luo Y et al (2025) Ciclosporin A potentiates venetoclax efficacy in FLT3-ITD AML by targeting the NFATC1-AKT-mTOR-BCL-2\/MCL-1 signaling axis. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.20137","DOI":"10.1111\/bjh.20137"},{"issue":"1","key":"6710_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12672-025-02242-7","volume":"16","author":"F Li","year":"2025","unstructured":"Li F et al (2025) A combination of dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC\/BCL-XL\/MCL-1 triple targeting. Discov Oncol 16(1):496","journal-title":"Discov Oncol"},{"key":"6710_CR16","doi-asserted-by":"publisher","first-page":"1530270","DOI":"10.3389\/fphar.2025.1530270","volume":"16","author":"M Xu","year":"2025","unstructured":"Xu M et al (2025) 20(S)-protopanaxadiol inhibits proliferation and induces apoptosis of acute myeloid leukemia cells via targeting Bcl-X(L) and MCL-1. Front Pharmacol 16:1530270","journal-title":"Front Pharmacol"},{"issue":"4","key":"6710_CR17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.62940\/als.v10i4.2200","volume":"10","author":"N Helmi","year":"2023","unstructured":"Helmi N (2023) Identification of therapeutic phytochemicals targeting B-cell lymphoma 2 (BCL2) as anti-acute myeloid leukemia agents: an in-silico approach. Adv Life Sci 10(4):670\u2013674","journal-title":"Adv Life Sci"},{"issue":"3","key":"6710_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/aps.2014.141","volume":"36","author":"XX Xiong","year":"2015","unstructured":"Xiong XX et al (2015) Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38\/JNK pathways. Acta Pharmacol Sin 36(3):362\u2013374","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"6710_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/jcb.22044","volume":"106","author":"G Marfe","year":"2009","unstructured":"Marfe G et al (2009) Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. J Cell Biochem 106(4):643\u2013650","journal-title":"J Cell Biochem"},{"issue":"1","key":"6710_CR20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/ijms16010645","volume":"16","author":"C Park","year":"2014","unstructured":"Park C et al (2014) Morin, a flavonoid from moraceae, induces apoptosis by induction of BAD protein in human leukemic cells. Int J Mol Sci 16(1):645\u2013659","journal-title":"Int J Mol Sci"},{"key":"6710_CR21","unstructured":"Wei Chang JW, Yi Xiao (2020) Friedelin inhibits the growth and metastasis of human leukemia cells via modulation of MEK\/ERK and PI3K\/AKT signalling pathways JBUON 25(3):1594\u20131599."},{"key":"6710_CR22","doi-asserted-by":"crossref","unstructured":"Yao Hu QL, Hui Zhao, Xiaojing Li, Shangyuan Sang, David Julian McClements, Jie Long, Zhengyu Jin, Jinpeng Wang, Chao Qiu (2023) Bioaccessibility and bioavailability of phytochemicals: Influencing factors, improvements, and evaluations. Food Hydrocolloids 135:108165.","DOI":"10.1016\/j.foodhyd.2022.108165"},{"issue":"1","key":"6710_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41419-025-07560-w","volume":"16","author":"CQ Jiao","year":"2025","unstructured":"Jiao CQ et al (2025) Targeting METTL3 mitigates venetoclax resistance via proteasome-mediated modulation of MCL1 in acute myeloid leukemia. Cell Death Dis 16(1):233","journal-title":"Cell Death Dis"},{"key":"6710_CR24","doi-asserted-by":"crossref","unstructured":"Chakraborty S et al (2024) A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia. bioRxiv.","DOI":"10.1101\/2024.08.05.599788"},{"issue":"1","key":"6710_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1182\/bloodadvances.2024014446","volume":"9","author":"FC Brown","year":"2025","unstructured":"Brown FC et al (2025) Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia. Blood Adv 9(1):127\u2013131","journal-title":"Blood Adv"},{"key":"6710_CR26","doi-asserted-by":"publisher","first-page":"1501950","DOI":"10.3389\/fonc.2024.1501950","volume":"14","author":"M Markouli","year":"2024","unstructured":"Markouli M, Pagoni MN, Diamantopoulos P (2024) Bcl-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies. Front Oncol 14:1501950","journal-title":"Front Oncol"},{"issue":"5","key":"6710_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood.2024025563","volume":"145","author":"A Kumar","year":"2025","unstructured":"Kumar A et al (2025) Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood 145(5):497\u2013507","journal-title":"Blood"},{"issue":"1","key":"6710_CR28","doi-asserted-by":"publisher","first-page":"2338509","DOI":"10.1080\/16078454.2024.2338509","volume":"29","author":"X Wang","year":"2024","unstructured":"Wang X et al (2024) Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations. Hematology 29(1):2338509","journal-title":"Hematology"},{"key":"6710_CR29","doi-asserted-by":"publisher","unstructured":"Ikoma Y et al (2025) Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax\/azacitidine for AML. Leukemia. https:\/\/doi.org\/10.1038\/s41375-025-02625-3","DOI":"10.1038\/s41375-025-02625-3"},{"issue":"8041","key":"6710_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","volume":"636","author":"J Sango","year":"2024","unstructured":"Sango J et al (2024) Ras-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature 636(8041):241\u2013250","journal-title":"Nature"},{"issue":"9","key":"6710_CR31","first-page":"872","volume":"45","author":"PP Xu","year":"2024","unstructured":"Xu PP et al (2024) Ruxolitinib combined with venetoclax and azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review. Zhonghua Xue Ye Xue Za Zhi 45(9):872\u2013875","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"6710_CR32","doi-asserted-by":"publisher","unstructured":"Wang L et al (2025) Clinical and molecular predictors of response and survival following venetoclax plus hypomethylating agents in relapsed\/refractory acute myeloid leukemia: a single-center study in Chinese patients. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17040586","DOI":"10.3390\/cancers17040586"},{"issue":"1","key":"6710_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s40001-025-02637-w","volume":"30","author":"W Shu","year":"2025","unstructured":"Shu W et al (2025) Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia. Eur J Med Res 30(1):354","journal-title":"Eur J Med Res"},{"issue":"3","key":"6710_CR34","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41375-024-02501-6","volume":"39","author":"R Shahswar","year":"2025","unstructured":"Shahswar R et al (2025) A novel prognostic risk model for patients with refractory\/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. Leukemia 39(3):614\u2013622","journal-title":"Leukemia"},{"issue":"11","key":"6710_CR35","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1182\/blood.2023022480","volume":"144","author":"MC Kwon","year":"2024","unstructured":"Kwon MC et al (2024) Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood 144(11):1206\u20131220","journal-title":"Blood"},{"issue":"21","key":"6710_CR36","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood.2024024944","volume":"144","author":"H Dohner","year":"2024","unstructured":"Dohner H et al (2024) Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood 144(21):2211\u20132222","journal-title":"Blood"},{"issue":"1","key":"6710_CR37","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1182\/blood-2023-189435","volume":"142","author":"AF Irene Zacheo","year":"2023","unstructured":"Irene Zacheo AF (2023) Eugenio Fonzi, Maria Teresa Bochicchio, Giorgia Capirossi, Jacopo Nanni, Matteo Paganelli, Chiara Servilli, Lorenzo Ledda, Martina Ghetti, Mouna Jandoubi, Matteo Marchesini, Agnese Mattei, Giovanni Martinelli, Giovanni Marconi, Giorgia Simonetti, Novel Mechanisms of Venetoclax Resistance in Acute Myeloid Leukemia Based on Genomic Rearrangements. Blood 142(1):4165","journal-title":"Blood"},{"issue":"8","key":"6710_CR38","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/ajh.27366","volume":"99","author":"J Bewersdorf","year":"2024","unstructured":"Bewersdorf J et al (2024) Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-a multicenter cohort study. Am J Hematol 99(8):1640\u20131643","journal-title":"Am J Hematol"},{"key":"6710_CR39","doi-asserted-by":"publisher","first-page":"1456832","DOI":"10.3389\/fonc.2025.1456832","volume":"15","author":"T Wang","year":"2025","unstructured":"Wang T et al (2025) The association of FAT1 mutations with therapeutic outcomes in AML, especially in receiving venetoclax combination. Front Oncol 15:1456832","journal-title":"Front Oncol"},{"key":"6710_CR40","doi-asserted-by":"publisher","first-page":"107500","DOI":"10.1016\/j.leukres.2024.107500","volume":"141","author":"G Berton","year":"2024","unstructured":"Berton G et al (2024) Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia. Leuk Res 141:107500","journal-title":"Leuk Res"},{"key":"6710_CR41","doi-asserted-by":"publisher","unstructured":"Poonsombudlert K et al (2025) Effect of NPM1 mutation subtype and co-mutation patterns on the outcomes of acute myeloid leukemia. Eur J Haematol. https:\/\/doi.org\/10.1111\/ejh.14415","DOI":"10.1111\/ejh.14415"},{"issue":"1","key":"6710_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","volume":"34","author":"R Bisaillon","year":"2020","unstructured":"Bisaillon R et al (2020) Genetic characterization of ABT-199 sensitivity in human AML. Leukemia 34(1):63\u201374","journal-title":"Leukemia"},{"issue":"3","key":"6710_CR43","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/jha2.922","volume":"5","author":"H Sun","year":"2024","unstructured":"Sun H et al (2024) PICALM::MLLT10 may indicate a new subgroup of acute leukemias with miscellaneous immunophenotype and poor initial treatment response but showing sensitivity to venetoclax. EJHaem 5(3):565\u2013572","journal-title":"EJHaem"},{"issue":"4","key":"6710_CR44","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1007\/s00277-025-06312-2","volume":"104","author":"K Yang","year":"2025","unstructured":"Yang K et al (2025) Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+\/FLT3-ITD + acute myeloid leukemia. Ann Hematol 104(4):2545\u20132549","journal-title":"Ann Hematol"},{"issue":"1","key":"6710_CR45","doi-asserted-by":"publisher","first-page":"2439110","DOI":"10.1080\/16078454.2024.2439110","volume":"30","author":"YZ Liu","year":"2025","unstructured":"Liu YZ et al (2025) Identification of t(X;1)(q28;q21) generating a novel GATAD2B::MTCP1 gene fusion in CMML and its persistence during progression to AML. Hematology 30(1):2439110","journal-title":"Hematology"},{"key":"6710_CR46","doi-asserted-by":"publisher","unstructured":"Ha YN et al (2020) Petromurin c induces protective autophagy and apoptosis in FLT3-ITD-positive AML: synergy with Gilteritinib. Mar Drugs. https:\/\/doi.org\/10.3390\/md18010057","DOI":"10.3390\/md18010057"},{"key":"6710_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1756-8722-6-21","volume":"6","author":"H Alachkar","year":"2013","unstructured":"Alachkar H et al (2013) Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. J Hematol Oncol 6:21","journal-title":"J Hematol Oncol"},{"key":"6710_CR48","first-page":"170","volume":"37","author":"B Sparks","year":"2013","unstructured":"Sparks B, Perkins HE, Buckley R (2013) Online travel reviews as persuasive communication: the effects of content type, source, and certification logos on consumer behavior. Tour Manage 37:170\u2013179","journal-title":"Tour Manage"},{"key":"6710_CR49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40170-019-0198-7","volume":"7","author":"TH Peeters","year":"2019","unstructured":"Peeters TH et al (2019) Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer Metab 7:4","journal-title":"Cancer Metab"},{"issue":"5","key":"6710_CR50","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cmet.2019.01.011","volume":"29","author":"KH Lin","year":"2019","unstructured":"Lin KH et al (2019) Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. Cell Metab 29(5):1217\u20131231 e7.","journal-title":"Cell Metab"},{"key":"6710_CR51","doi-asserted-by":"publisher","unstructured":"Sharon D et al (2019) Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aax2863","DOI":"10.1126\/scitranslmed.aax2863"},{"key":"6710_CR52","doi-asserted-by":"publisher","first-page":"107054","DOI":"10.1016\/j.leukres.2023.107054","volume":"128","author":"RSS Illangeswaran","year":"2023","unstructured":"Illangeswaran RSS et al (2023) Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines. Leuk Res 128:107054","journal-title":"Leuk Res"},{"key":"6710_CR53","doi-asserted-by":"publisher","unstructured":"Lima K et al (2023) Pharmacological inhibition of PIP4K2 potentiates venetoclax-induced apoptosis in acute myeloid leukemia. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms242316899","DOI":"10.3390\/ijms242316899"},{"issue":"1","key":"6710_CR54","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13046-022-02542-8","volume":"41","author":"K Fooks","year":"2022","unstructured":"Fooks K et al (2022) EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax. J Exp Clin Cancer Res 41(1):340","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"6710_CR55","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X et al (2019) Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov 9(7):890\u2013909","journal-title":"Cancer Discov"},{"issue":"7","key":"6710_CR56","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1002\/fsn3.3420","volume":"11","author":"C Egbuna","year":"2023","unstructured":"Egbuna C et al (2023) Phytochemicals and bioactive compounds effective against acute myeloid leukemia: a systematic review. Food Sci Nutr 11(7):4191\u20134210","journal-title":"Food Sci Nutr"},{"key":"6710_CR57","doi-asserted-by":"publisher","unstructured":"Zhou H et al (2021) Curcumin promotes cell cycle arrest and apoptosis of acute myeloid leukemia cells by inactivating AKT. Oncol Rep. https:\/\/doi.org\/10.3892\/or.2021.7962","DOI":"10.3892\/or.2021.7962"},{"key":"6710_CR58","doi-asserted-by":"publisher","first-page":"106644","DOI":"10.1016\/j.compbiomed.2023.106644","volume":"155","author":"J Brahmbhatt","year":"2023","unstructured":"Brahmbhatt J et al (2023) Targeting leukemic stem cell subpopulation in AML using phytochemicals: an in-silico and in-vitro approach. Comput Biol Med 155:106644","journal-title":"Comput Biol Med"},{"issue":"1","key":"6710_CR59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1142\/S0192415X16500117","volume":"44","author":"ZY Li","year":"2016","unstructured":"Li ZY et al (2016) Sophoraflavanone G Induces Apoptosis in Human Leukemia Cells and Blocks MAPK Activation. Am J Chin Med 44(1):165\u2013176","journal-title":"Am J Chin Med"},{"issue":"4","key":"6710_CR60","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1007\/s10528-023-10582-8","volume":"62","author":"M Iravani Saadi","year":"2024","unstructured":"Iravani Saadi M et al (2024) The effects of resveratrol, gallic acid, and piperine on the expression of miR-17, miR-92b, miR-181a, miR-222, BAX, BCL-2, MCL-1, WT1, c-Kit, and CEBPA in human acute myeloid leukemia cells and their roles in apoptosis. Biochem Genet 62(4):2958\u20132974","journal-title":"Biochem Genet"},{"issue":"42","key":"6710_CR61","doi-asserted-by":"publisher","first-page":"10063","DOI":"10.1021\/jf402956m","volume":"61","author":"PC Hsiao","year":"2013","unstructured":"Hsiao PC et al (2013) Hispolon induces apoptosis through JNK1\/2-mediated activation of a caspase-8, -9, and -3-dependent pathway in acute myeloid leukemia (AML) cells and inhibits AML xenograft tumor growth in vivo. J Agric Food Chem 61(42):10063\u201310073","journal-title":"J Agric Food Chem"},{"issue":"1","key":"6710_CR62","first-page":"2083","volume":"134","author":"YS Bing Xu","year":"2019","unstructured":"Bing Xu YS, Liu Long, Carter Bing Z (2019) Combination of BCL-2 Inhibition and Triptolide Causes Synthetic Lethality in Acute Myeloid Leukemia through Preventing Reciprocal Resistance. Blood 134(1):2083","journal-title":"Blood"},{"issue":"7","key":"6710_CR63","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41419-020-02762-w","volume":"11","author":"YF Shi","year":"2020","unstructured":"Shi YF et al (2020) Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. Cell Death Dis 11(7):555","journal-title":"Cell Death Dis"},{"issue":"23","key":"6710_CR64","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1182\/blood.V126.23.2531.2531","volume":"126","author":"WJB Paraskevi Diamanti","year":"2015","unstructured":"Paraskevi Diamanti WJB, Ede Benjamin C, Cox Charlotte V, Blair Allison (2015) Combining BCL-2 Inhibitors with Parthenolide to Treat Childhood Acute Lymphoblastic Leukaemia. Blood 126(23):2531","journal-title":"Blood"},{"issue":"2","key":"6710_CR65","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40846-024-00911-6","volume":"44","author":"SA Yumo Jiao","year":"2024","unstructured":"Yumo Jiao SA, HussainHaiyan Hu, (2024) A pH-Sensitive Curcumin\/Crocetin-Loaded Chitosan Nanoparticles for Treating Acute Myeloid Leukemia: An in Vitro Study. J Med Biol Eng 44(2):859\u2013870","journal-title":"J Med Biol Eng"},{"key":"6710_CR66","doi-asserted-by":"publisher","unstructured":"Darwish NHE et al (2019) Novel targeted nano-parthenolide molecule against NF-kB in acute myeloid leukemia. Molecules. https:\/\/doi.org\/10.3390\/molecules24112103","DOI":"10.3390\/molecules24112103"},{"issue":"Pt 2","key":"6710_CR67","doi-asserted-by":"publisher","first-page":"132252","DOI":"10.1016\/j.ijbiomac.2024.132252","volume":"270","author":"TA Seaf Elnasr","year":"2024","unstructured":"Seaf Elnasr TA et al (2024) Olive leaf extract-derived chitosan-metal nanocomposite: Green synthesis and dual antimicrobial-anticancer action. Int J Biol Macromol 270(Pt 2):132252","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"6710_CR68","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s11033-024-10039-0","volume":"51","author":"C Ragavendran","year":"2024","unstructured":"Ragavendran C et al (2024) Eco-friendly synthesis of betanin-conjugated zinc oxide nanoparticles: antimicrobial efficacy and apoptotic pathway activation in oral cancer cells. Mol Biol Rep 51(1):1128","journal-title":"Mol Biol Rep"},{"issue":"11","key":"6710_CR69","doi-asserted-by":"publisher","first-page":"e31925","DOI":"10.1016\/j.heliyon.2024.e31925","volume":"10","author":"R Afarin","year":"2024","unstructured":"Afarin R et al (2024) Combination of etoposide and quercetin-loaded solid lipid nanoparticles potentiates apoptotic effects on MDA-MB-231 breast cancer cells. Heliyon 10(11):e31925","journal-title":"Heliyon"},{"issue":"1","key":"6710_CR70","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40659-021-00330-w","volume":"54","author":"XB Jia","year":"2021","unstructured":"Jia XB et al (2021) Lotus leaf flavonoids induce apoptosis of human lung cancer A549 cells through the ROS\/p38 MAPK pathway. Biol Res 54(1):7","journal-title":"Biol Res"},{"issue":"1","key":"6710_CR71","doi-asserted-by":"publisher","first-page":"10322","DOI":"10.1038\/s41598-021-89420-z","volume":"11","author":"MA Khan","year":"2021","unstructured":"Khan MA et al (2021) Phytochemicals from Ajwa dates pulp extract induce apoptosis in human triple-negative breast cancer by inhibiting AKT\/mTOR pathway and modulating Bcl-2 family proteins. Sci Rep 11(1):10322","journal-title":"Sci Rep"},{"issue":"9","key":"6710_CR72","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12032-024-02459-6","volume":"41","author":"S Bhuker","year":"2024","unstructured":"Bhuker S et al (2024) Allicin: a promising modulator of apoptosis and survival signaling in cancer. Med Oncol 41(9):210","journal-title":"Med Oncol"},{"issue":"8","key":"6710_CR73","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1002\/ptr.8269","volume":"38","author":"NA Cacciola","year":"2024","unstructured":"Cacciola NA et al (2024) Zosterabisphenone B, a new diarylheptanoid heterodimer from the seagrass Zostera marina, induces apoptosis cell death in colon cancer cells and reduces tumour growth in mice. Phytother Res 38(8):4168\u20134176","journal-title":"Phytother Res"},{"issue":"11","key":"6710_CR74","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1007\/s12010-022-04001-8","volume":"194","author":"H Zhou","year":"2022","unstructured":"Zhou H, Li F, Li Y (2022) Anti-cancer activity of Gedunin by induction of apoptosis in human gastric cancer AGS cells. Appl Biochem Biotechnol 194(11):5322\u20135332","journal-title":"Appl Biochem Biotechnol"},{"issue":"1","key":"6710_CR75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12906-022-03533-0","volume":"22","author":"MA Khan","year":"2022","unstructured":"Khan MA et al (2022) Anticancer potential of Phoenix dactylifera L. seed extract in human cancer cells and pro-apoptotic effects mediated through caspase-3 dependent pathway in human breast cancer MDA-MB-231 cells: an in vitro and in silico investigation. BMC Complement Med Ther 22(1):68","journal-title":"BMC Complement Med Ther"},{"key":"6710_CR76","doi-asserted-by":"publisher","first-page":"1078642","DOI":"10.3389\/fnut.2022.1078642","volume":"9","author":"M Suhail","year":"2022","unstructured":"Suhail M et al (2022) Targeting a transcription factor NF-kappaB by green tea catechins using in silico and in vitro studies in pancreatic cancer. Front Nutr 9:1078642","journal-title":"Front Nutr"},{"issue":"12","key":"6710_CR77","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.32604\/or.2024.048007","volume":"32","author":"Y Yin","year":"2024","unstructured":"Yin Y et al (2024) Caffeic acid hinders the proliferation and migration through inhibition of IL-6 mediated JAK-STAT-3 signaling axis in human prostate cancer. Oncol Res 32(12):1881\u20131890","journal-title":"Oncol Res"},{"issue":"6","key":"6710_CR78","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jtcme.2024.04.003","volume":"14","author":"S Upadhyay","year":"2024","unstructured":"Upadhyay S et al (2024) Exploring the ROS-mediated anti-cancer potential in human triple-negative breast cancer by garlic bulb extract: a source of therapeutically active compounds. J Tradit Complement Med 14(6):644\u2013655","journal-title":"J Tradit Complement Med"},{"issue":"3","key":"6710_CR79","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.31557\/APJCP.2024.25.3.1065","volume":"25","author":"JV Changade","year":"2024","unstructured":"Changade JV et al (2024) In vitro evaluation of anti-cancer potential of different solvent extracts derived from Clerodendrum infortunatum Linn against cervical cancer. Asian Pac J Cancer Prev 25(3):1065\u20131075","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"6710_CR80","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3892\/ol.2024.14473","volume":"28","author":"C Xiong","year":"2024","unstructured":"Xiong C et al (2024) 3,3\u2019-diindolylmethane inhibits the proliferation of esophageal squamous cell carcinoma cells via downregulation of STIM1. Oncol Lett 28(2):339","journal-title":"Oncol Lett"},{"issue":"6","key":"6710_CR81","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2174\/1386207324666210302095557","volume":"25","author":"T Jalal","year":"2022","unstructured":"Jalal T, Natto HA, Wahab RA (2022) Cytotoxicity and toxicological studies of Artocarpus altilis extracts, inducing apoptosis and cell cycle arrest via CASPASE-3 and CASPASE-8 pathways against human breast MCF-7 cells. Comb Chem High Throughput Screen 25(6):973\u2013985","journal-title":"Comb Chem High Throughput Screen"},{"issue":"7","key":"6710_CR82","first-page":"e64739","volume":"16","author":"B Vincer","year":"2024","unstructured":"Vincer B et al (2024) Exploring the cytotoxic and anticancer potential of Naringin on oral cancer cell line. Cureus 16(7):e64739","journal-title":"Cureus"},{"issue":"7","key":"6710_CR83","first-page":"e65286","volume":"16","author":"S Somesh","year":"2024","unstructured":"Somesh S, Rajanathadurai J, Perumal E (2024) Pycnogenol\u2019s dual impact: inducing apoptosis and suppressing migration via vascular endothelial growth factor\/fibroblast growth factor signaling pathways in breast cancer cells. Cureus 16(7):e65286","journal-title":"Cureus"},{"key":"6710_CR84","doi-asserted-by":"publisher","unstructured":"Xu F et al (2024) 3,5-DCQA as a major molecule in MeJA-treated Dendropanax morbifera adventitious root to promote anti-lung cancer and anti-inflammatory activities. Biomolecules. https:\/\/doi.org\/10.3390\/biom14060705","DOI":"10.3390\/biom14060705"},{"issue":"Pt 3","key":"6710_CR85","doi-asserted-by":"publisher","first-page":"119102","DOI":"10.1016\/j.jep.2024.119102","volume":"338","author":"Z Wu","year":"2025","unstructured":"Wu Z et al (2025) Safety assessment and exploration of the mechanism of toxic effects of diallyl trisulfide: Based on acute and subacute toxicity and proteomics experiments. J Ethnopharmacol 338(Pt 3):119102","journal-title":"J Ethnopharmacol"},{"key":"6710_CR86","doi-asserted-by":"publisher","unstructured":"Erdogan MK, Usca AB (2025) Gallic acid enhances Olaparib-induced cell death and attenuates Olaparib resistance in human osteosarcoma U2OS cell line. Curr Issues Mol Biol. https:\/\/doi.org\/10.3390\/cimb47020104","DOI":"10.3390\/cimb47020104"},{"issue":"12","key":"6710_CR87","doi-asserted-by":"publisher","first-page":"e0309258","DOI":"10.1371\/journal.pone.0309258","volume":"19","author":"G Moriasi","year":"2024","unstructured":"Moriasi G et al (2024) Antioxidant, anti-prostate cancer potential, and phytochemical composition of the ethyl acetate stem bark extract of Boascia coriacea (Pax.). PLoS ONE 19(12):e0309258","journal-title":"PLoS ONE"},{"key":"6710_CR88","doi-asserted-by":"crossref","unstructured":"Verma M et al (2025) 3-Acetyl-11-keto-beta-boswellic acid (AKBA) induced antiproliferative effect by suppressing Notch signaling pathway and synergistic interaction with cisplatin against prostate cancer cells. Naunyn Schmiedebergs Arch Pharmacol.","DOI":"10.1007\/s00210-025-03899-1"},{"issue":"3","key":"6710_CR89","doi-asserted-by":"publisher","first-page":"483","DOI":"10.4062\/biomolther.2024.239","volume":"33","author":"D Lee","year":"2025","unstructured":"Lee D et al (2025) 1,3,5-Tricaffeoylquinic Acid from Ipomoea batatas Vines Induced Ovarian Cancer Cell Apoptosis and Inhibited Endothelial Tube Formation. Biomol Ther (Seoul) 33(3):483\u2013493","journal-title":"Biomol Ther (Seoul)"},{"key":"6710_CR90","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.freeradbiomed.2024.12.059","volume":"228","author":"DJ Das","year":"2025","unstructured":"Das DJ et al (2025) Ethanolic extract of Akhuni induces ROS-mediated apoptosis through ERK and AKT signalling pathways: insights from metabolic profiling and molecular docking studies. Free Radic Biol Med 228:137\u2013149","journal-title":"Free Radic Biol Med"},{"key":"6710_CR91","doi-asserted-by":"crossref","unstructured":"Li H et al (2025) Pharmacological Evaluation of Amorphophalli rhizoma to Inhibit the Progression of Estrogen Receptor+ (ER+) Breast Cancer by Modulating the PI3K\/AKT Cell Signaling Pathway. Curr Cancer Drug Targets.","DOI":"10.2174\/0115680096360994250106082347"},{"key":"6710_CR92","doi-asserted-by":"publisher","unstructured":"Babaei Z, Ghanadian M, Aghaei M (2025) Disafynol: A polyacetylene dimer from Centaurea schmidii enhancing breast cancer cell apoptosis via oxidative and ER stress pathways. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04085-z","DOI":"10.1007\/s00210-025-04085-z"},{"issue":"5","key":"6710_CR93","doi-asserted-by":"publisher","first-page":"e0320849","DOI":"10.1371\/journal.pone.0320849","volume":"20","author":"YF Su","year":"2025","unstructured":"Su YF et al (2025) Mitochondrial dysfunction and cell death induced by Toona sinensis leaf extracts through MEK\/ERK signaling in glioblastoma cells. PLoS ONE 20(5):e0320849","journal-title":"PLoS ONE"},{"key":"6710_CR94","doi-asserted-by":"publisher","unstructured":"Gorrie D, Bravo M, Fan L (2024) The yin and yang of the natural product Triptolide and its interactions with XPB, an essential protein for gene expression and DNA repair. Genes. https:\/\/doi.org\/10.3390\/genes15101287","DOI":"10.3390\/genes15101287"},{"issue":"13","key":"6710_CR95","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1182\/blood-2007-05-090621","volume":"110","author":"ML Guzman","year":"2007","unstructured":"Guzman ML et al (2007) An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110(13):4427\u20134435","journal-title":"Blood"},{"key":"6710_CR96","doi-asserted-by":"crossref","unstructured":"Chenyu Bai XH, Shuyu Lu, Bo Xu, Tao Ma, Yi Song, (2025) Recent advances and application challenges of quercetin-loaded delivery systems: from material selection to bioavailability. J of Future Foods.","DOI":"10.1016\/j.jfutfo.2025.01.014"},{"key":"6710_CR97","doi-asserted-by":"crossref","unstructured":"Mariane Cristina Do Nascimento DAP-M, Guilherme Augusto Sousa Alc\u00e2ntara, Keli Lima, Hugo Passos Vicari, Marcelo Jos\u00e9 Pena Ferreira, Leticia Veras Costa-Lotufo, Gerwin A. Huls, Jan Jacob Schuringa, Jo\u00e3o Agostinho Machado-Neto, Eduardo Magalh\u00e3es Rego (2023) Cephalochromin-Induced Mitochondrial Damage Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia Models. Blood 142(1):5751.","DOI":"10.1182\/blood-2023-189814"},{"key":"6710_CR98","doi-asserted-by":"publisher","unstructured":"Schiffmann S et al (2022) In vitro safety, off-target and bioavailability profile of the antiviral compound Silvestrol. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph15091086","DOI":"10.3390\/ph15091086"},{"key":"6710_CR99","doi-asserted-by":"publisher","first-page":"117047","DOI":"10.1016\/j.biopha.2024.117047","volume":"177","author":"G Peron","year":"2024","unstructured":"Peron G et al (2024) Silvestrol, a potent anticancer agent with unfavourable pharmacokinetics: current knowledge on its pharmacological properties and future directions for the development of novel drugs. Biomed Pharmacother 177:117047","journal-title":"Biomed Pharmacother"},{"key":"6710_CR100","first-page":"1115","volume":"7","author":"ZQ Chen","year":"2012","unstructured":"Chen ZQ et al (2012) Improved oral bioavailability of poorly water-soluble indirubin by a supersaturatable self-microemulsifying drug delivery system. Int J Nanomedicine 7:1115\u20131125","journal-title":"Int J Nanomedicine"},{"key":"6710_CR101","doi-asserted-by":"publisher","unstructured":"He E et al (2022) Transdermal delivery of Indirubin-loaded microemulsion gel: preparation, characterization and anti-psoriatic activity. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23073798","DOI":"10.3390\/ijms23073798"},{"key":"6710_CR102","doi-asserted-by":"publisher","first-page":"654098","DOI":"10.1155\/2015\/654098","volume":"2015","author":"T Blazevic","year":"2015","unstructured":"Blazevic T et al (2015) Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases. Evid Based Complement Alternat Med 2015:654098","journal-title":"Evid Based Complement Alternat Med"},{"key":"6710_CR103","doi-asserted-by":"crossref","unstructured":"Andreu-Fernandez V et al (2020) Bioavailability of Epigallocatechin Gallate Administered With Different Nutritional Strategies in Healthy Volunteers. Antioxidants (Basel) 9(5).","DOI":"10.3390\/antiox9050440"},{"issue":"5","key":"6710_CR104","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1208\/s12249-025-03145-0","volume":"26","author":"M Qutub","year":"2025","unstructured":"Qutub M et al (2025) Nano-engineered Epigallocatechin Gallate (EGCG) delivery systems: overcoming bioavailability barriers to unlock clinical potential in cancer therapy. AAPS PharmSciTech 26(5):137","journal-title":"AAPS PharmSciTech"},{"key":"6710_CR105","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jff.2017.01.022","volume":"30","author":"AS Dharambir Kashyap","year":"2017","unstructured":"Dharambir Kashyap AS, Tapan Hardeep Singh Tuli Katrin Sak Sandeep Punia, Mukherjee K (2017) Kaempferol \u2013 A dietary anticancer molecule with multiple mechanisms of action: Recent trends and advancements. J Functional Foods 30:203\u2013219","journal-title":"J Functional Foods"},{"key":"6710_CR106","doi-asserted-by":"crossref","unstructured":"Vani Vijay, MKP (2015) Morin, a Polypharmacological Marvel: Unveiling its versatility and recent advances in bioavailability enhancement. Food Bioscience 65.","DOI":"10.1016\/j.fbio.2025.106104"},{"key":"6710_CR107","doi-asserted-by":"publisher","first-page":"123212","DOI":"10.1016\/j.ijpharm.2023.123212","volume":"643","author":"SK Shama Parveen","year":"2023","unstructured":"Shama Parveen SK (2023) Sarita Pal, Narayan Prasad Yadav, Jyotika Rajawat, Monisha Banerjee, Enhanced therapeutic efficacy of Piperlongumine for cancer treatment using nano-liposomes mediated delivery. Int J Pharm 643:123212","journal-title":"Int J Pharm"},{"issue":"2","key":"6710_CR108","doi-asserted-by":"publisher","first-page":"133738","DOI":"10.1016\/j.ijbiomac.2024.133738","volume":"275","author":"SK Ashok Kumar Jangid","year":"2024","unstructured":"Ashok Kumar Jangid SK, Kyobum Kim (2024)\u00a0Delivery of piperlongumine via hyaluronic acid\/phenylboronic acid-mediated dual targetable polymersome for enhanced anticancer functionality against pancreatic tumor. Int J Biol Macromol\u00a0275(2):133738.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"6710_CR109","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/01635581.2019.1578387","volume":"71","author":"Y Li","year":"2019","unstructured":"Li Y et al (2019) Involvement of the PI3K\/Akt\/Nrf2 signaling pathway in resveratrol-mediated reversal of drug resistance in HL-60\/ADR cells. Nutr Cancer 71(6):1007\u20131018","journal-title":"Nutr Cancer"},{"issue":"6","key":"6710_CR110","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1182\/blood-2006-02-003988","volume":"109","author":"A Bhardwaj","year":"2007","unstructured":"Bhardwaj A et al (2007) Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109(6):2293\u20132302","journal-title":"Blood"},{"key":"6710_CR111","doi-asserted-by":"publisher","unstructured":"Chimento A et al (2019) Progress to improve oral bioavailability and beneficial effects of resveratrol. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20061381","DOI":"10.3390\/ijms20061381"},{"key":"6710_CR112","doi-asserted-by":"publisher","unstructured":"Tomou EM et al (2023) Recent advances in nanoformulations for quercetin delivery. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15061656","DOI":"10.3390\/pharmaceutics15061656"},{"issue":"1","key":"6710_CR113","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1080\/10717544.2022.2122634","volume":"29","author":"NK Alruwaili","year":"2022","unstructured":"Alruwaili NK et al (2022) Development of surface modified bilosomes for the oral delivery of quercetin: optimization, characterization in-vitro antioxidant, antimicrobial, and cytotoxicity study. Drug Deliv 29(1):3035\u20133050","journal-title":"Drug Deliv"},{"issue":"1","key":"6710_CR114","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1080\/10717544.2021.1927244","volume":"28","author":"H Li","year":"2021","unstructured":"Li H et al (2021) Enhancement of oral bioavailability of quercetin by metabolic inhibitory nanosuspensions compared to conventional nanosuspensions. Drug Deliv 28(1):1226\u20131236","journal-title":"Drug Deliv"},{"issue":"1","key":"6710_CR115","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13880209.2019.1701042","volume":"58","author":"G Zhu","year":"2020","unstructured":"Zhu G et al (2020) Curcumin inhibited the growth and invasion of human monocytic leukaemia SHI-1 cells in vivo by altering MAPK and MMP signalling. Pharm Biol 58(1):25\u201334","journal-title":"Pharm Biol"},{"issue":"12","key":"6710_CR116","doi-asserted-by":"publisher","first-page":"10713","DOI":"10.1021\/acsomega.2c07326","volume":"8","author":"M Hegde","year":"2023","unstructured":"Hegde M et al (2023) Curcumin formulations for better bioavailability: what we learned from clinical trials thus far? ACS Omega 8(12):10713\u201310746","journal-title":"ACS Omega"},{"issue":"1\u20132","key":"6710_CR117","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11010-017-3171-1","volume":"441","author":"K Yamagata","year":"2018","unstructured":"Yamagata K et al (2018) Chlorogenic acid regulates apoptosis and stem cell marker-related gene expression in A549 human lung cancer cells. Mol Cell Biochem 441(1\u20132):9\u201319","journal-title":"Mol Cell Biochem"},{"key":"6710_CR118","doi-asserted-by":"publisher","unstructured":"Nguyen V et al (2024) Chlorogenic acid: a systematic review on the biological functions, mechanistic actions, and therapeutic potentials. Nutrients. https:\/\/doi.org\/10.3390\/nu16070924","DOI":"10.3390\/nu16070924"},{"key":"6710_CR119","doi-asserted-by":"crossref","unstructured":"Trivedi HR, Puranik PK (2023) Chlorogenic acid-optimized nanophytovesicles: a novel approach for enhanced permeability and oral bioavailability. Futur J Pharm Sci 9(116).","DOI":"10.1186\/s43094-023-00559-0"},{"key":"6710_CR120","doi-asserted-by":"publisher","first-page":"114694","DOI":"10.1016\/j.ejmech.2022.114694","volume":"243","author":"D Kang","year":"2022","unstructured":"Kang D et al (2022) Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia. Eur J Med Chem 243:114694","journal-title":"Eur J Med Chem"},{"issue":"5","key":"6710_CR121","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.pharep.2017.04.012","volume":"69","author":"JA Lee","year":"2017","unstructured":"Lee JA et al (2017) Effects of friedelin on the intestinal permeability and bioavailability of apigenin. Pharmacol Rep 69(5):1044\u20131048","journal-title":"Pharmacol Rep"},{"issue":"2","key":"6710_CR122","doi-asserted-by":"publisher","first-page":"88","DOI":"10.33263\/LIANBS132.088","volume":"13","author":"P Chaturvedi","year":"2024","unstructured":"Chaturvedi P, Sharma P (2024) Formulation and in vitro evaluation of Holoptelea integrifolia Planch. extract loaded solid lipid nanoparticles. Lett Appl NanoBiosci 13(2):88","journal-title":"Lett Appl NanoBiosci"},{"key":"6710_CR123","doi-asserted-by":"publisher","unstructured":"Singh SK et al (2023) Friedelin: structure, biosynthesis, extraction, and its potential health impact. Molecules. https:\/\/doi.org\/10.3390\/molecules28237760","DOI":"10.3390\/molecules28237760"},{"key":"6710_CR124","doi-asserted-by":"publisher","first-page":"105207","DOI":"10.1016\/j.tiv.2021.105207","volume":"76","author":"CSM Reis-Silva","year":"2021","unstructured":"Reis-Silva CSM et al (2021) Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells. Toxicol In Vitro 76:105207","journal-title":"Toxicol In Vitro"},{"issue":"10","key":"6710_CR125","first-page":"1228","volume":"27","author":"A Ali","year":"2024","unstructured":"Ali A et al (2024) Medicinal potential of embelin and its nanoformulations: an update on the molecular mechanism and various applications. Iran J Basic Med Sci 27(10):1228\u20131242","journal-title":"Iran J Basic Med Sci"},{"issue":"2","key":"6710_CR126","first-page":"121","volume":"14","author":"AT Maliheh Entezari","year":"2024","unstructured":"Maliheh Entezari AT (2024) Mahshid Deldar Abad Paskeh. Simin Khorsand Kheirabad, Sahar Naeemi, Afshin Taheria, Curcumin in treatment of hematological cancers: Promises and challenges, Journal of Traditional and Complementary Medicine 14(2):121\u2013134","journal-title":"Simin Khorsand Kheirabad, Sahar Naeemi, Afshin Taheria, Curcumin in treatment of hematological cancers: Promises and challenges, Journal of Traditional and Complementary Medicine"},{"issue":"5","key":"6710_CR127","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41375-023-01874-4","volume":"37","author":"UA Shah","year":"2023","unstructured":"Shah UA et al (2023) Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders. Leukemia 37(5):964\u2013980","journal-title":"Leukemia"},{"key":"6710_CR128","doi-asserted-by":"publisher","unstructured":"Xie X et al (2021) Curcumin as an epigenetic therapeutic agent in myelodysplastic syndromes (MDS). Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23010411","DOI":"10.3390\/ijms23010411"},{"key":"6710_CR129","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/JEP.S427818","volume":"16","author":"VL Pratti","year":"2024","unstructured":"Pratti VL et al (2024) Investigating Bioavailability of Curcumin and Piperine Combination in Comparison to Turmeric Rhizomes: An in vitro Study. J Exp Pharmacol 16:37\u201347","journal-title":"J Exp Pharmacol"},{"key":"6710_CR130","doi-asserted-by":"publisher","first-page":"104890","DOI":"10.1016\/j.jff.2021.104890","volume":"88","author":"J-YX Qian He","year":"2022","unstructured":"Qian He J-YX, Jia Gu, Tong Xing, Wan Zhongxiao, Ying Gu, Fang Chen, Qin Li-Qiang (2022) Piperine is capable of improving pancreatic \u03b2-cell apoptosis in high fat diet and streptozotocin induced diabetic mice. J Functional Food 88:104890","journal-title":"J Functional Food"},{"issue":"1","key":"6710_CR131","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12967-019-1901-8","volume":"17","author":"B Giri","year":"2019","unstructured":"Giri B et al (2019) Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia. J Transl Med 17(1):163","journal-title":"J Transl Med"},{"issue":"5","key":"6710_CR132","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/jha2.994","volume":"5","author":"S Srinivasan","year":"2024","unstructured":"Srinivasan S (2024) Dasatinib in core-binding factor acute myeloid leukemia: a promising therapeutic approach. EJHaem 5(5):1100\u20131101","journal-title":"EJHaem"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06710-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06710-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06710-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:02:19Z","timestamp":1764730939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06710-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":132,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6710"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06710-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript has been read and approved by all the authors to publish and is not submitted or under consideration for publication elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}